390 related articles for article (PubMed ID: 12939590)
1. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Bressler BL; Guindi M; Tomlinson G; Heathcote J
Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
[TBL] [Abstract][Full Text] [Related]
2. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
5. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
6. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
8. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
Poustchi H; Negro F; Hui J; Cua IH; Brandt LR; Kench JG; George J
J Hepatol; 2008 Jan; 48(1):28-34. PubMed ID: 17977612
[TBL] [Abstract][Full Text] [Related]
10. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
11. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
12. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
[TBL] [Abstract][Full Text] [Related]
13. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
14. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
Patton HM; Patel K; Behling C; Bylund D; Blatt LM; Vallée M; Heaton S; Conrad A; Pockros PJ; McHutchison JG
J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin in the treatment of hepatitis C.
Abonyi ME; Lakatos PL
Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
[TBL] [Abstract][Full Text] [Related]
17. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
20. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]